Primary, post-primary and non-specific immunoglobulin M responses in HCV infection

Antiviral Therapy

Volumn 17, Issue 7 PARTB, 2012, Pages 1449-1452

  Dustin, Lynn B ^a   Charles, Edgar D ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD81 ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M; IMMUNOGLOBULIN M ANTIBODY; VIRUS ANTIGEN; VIRUS RNA;

ANTIBODY RESPONSE; B LYMPHOCYTE; CELL ACTIVATION; CRYOGLOBULINEMIA; DISEASE ASSOCIATION; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK PATIENT; HUMAN; IMMUNOPATHOGENESIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS REPLICATION;

ANTIGEN-ANTIBODY COMPLEX; B-LYMPHOCYTES; CRYOGLOBULINEMIA; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HEPATITIS C ANTIGENS; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LYMPHOCYTE ACTIVATION; MIDDLE AGED; RHEUMATOID FACTOR; RNA, VIRAL;

EID: 84871966094     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2222     Document Type: Review

References (56)

1. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29 Suppl 1:74-81.
2. CDC. Viral hepatitis surveillance. (Updated 22 June 2012. Assessed 31 August 2012.) Available from http://www.cdc.gov/hepatitis/Statistics/index.htm
3. Maheshwari A, Ray S, Thuluvath PJ. Acute hepatitis C. Lancet 2008; 372:321-332. (Pubitemid 352020441)
4. Dustin LB, Rice CM. Flying under the radar: the immunobiology of hepatitis C. Annu Rev Immunol 2007; 25:71-99. (Pubitemid 46697903)
5. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest 2009; 119:1745-1754.
6. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54:1433-1444.
7. Heathcote EJ. Antiviral therapy: chronic hepatitis C. J Viral Hepat 2007; 14 Suppl 1:82-88.
8. Grebely J, Matthews GV, Dore GJ. Treatment of acute HCV infection. Nat Rev Gastroenterol Hepatol 2011; 8:265-274.
9. Alter HJ, Purcell RH, Shih JW, et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989; 321:1494-1500. (Pubitemid 20015539)
10. Clemens JM, Taskar S, Chau K, et al. IgM antibody response in acute hepatitis C viral infection. Blood 1992; 79:169-172.
11. Netski DM, Mosbruger T, Depla E, et al. Humoral immune response in acute hepatitis C virus infection. Clin Infect Dis 2005; 41:667-675. (Pubitemid 41170355)
12. Sagnelli E, Coppola N, Marrocco C, et al. Diagnosis of hepatitis C virus related acute hepatitis by serial determination of IgM anti-HCV titres. J Hepatol 2005; 42:646-651.
13. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001; 194:1395-1406. (Pubitemid 33081515)
14. Pawlotsky JM, Darthuy F, Remire J, et al. Significance of anti-hepatitis C virus core IgM antibodies in patients with chronic hepatitis C. J Med Virol 1995; 47:285-291.
15. Yamaguchi N, Tokushige K, Yamauchi K, Hayashi N. Humoral immune response in Japanese acute hepatitis patients with hepatitis C virus infection. Can J Gastroenterol 2000; 14:593-598.
16. Lau GK, Lesniewski R, Johnson RG, Davis GL, Lau JY. Immunoglobulin M and A antibodies to hepatitis C core antigen in chronic hepatitis C virus infection. J Med Virol 1994; 44:1-4. (Pubitemid 24288118)
17. Sagnelli E, Coppola N, Marrocco C, et al. Diagnosis of HCV related acute hepatitis by serial determination of IgM to HCV: a preliminary observation. J Biol Regul Homeost Agents 2003; 17:207-210. (Pubitemid 37220858)
18. Chen PJ, Wang JT, Hwang LH, et al. Transient immunoglobulin M antibody response to hepatitis C virus capsid antigen in posttransfusion hepatitis C: putative serological marker for acute viral infection. Proc Natl Acad Sci U S A 1992; 89:5971-5975.
19. Logvinoff C, Major ME, Oldach D, et al. Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci U S A 2004; 101:10149-10154. (Pubitemid 38891210)
20. Nikolaeva LI, Blokhina NP, Tsurikova NN, et al. Virus-specific antibody titres in different phases of hepatitis C virus infection. J Viral Hepat 2002; 9:429-437. (Pubitemid 35373764)
21. Mayo MJ. Extrahepatic manifestations of hepatitis C infection. Am J Med Sci 2003; 325:135-148. (Pubitemid 36348619)
22. Giordano TP, Henderson L, Landgren O, et al. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA 2007; 297:2010-2017. (Pubitemid 46740353)
23. El-Serag HB, Hampel H, Yeh C, Rabeneck L. Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology 2002; 36:1439-1445. (Pubitemid 35403535)
24. De Re V, De Vita S, Marzotto A, et al. Sequence analysis of the immunoglobulin antigen receptor of hepatitis C virus-associated non-Hodgkin lymphomas suggests that the malignant cells are derived from the rheumatoid factor-producing cells that occur mainly in type II cryoglobulinemia. Blood 2000; 96:3578-3584.
25. Pawlotsky JM, Ben Yahia M, Andre C, et al. Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. Hepatology 1994; 19:841-848. (Pubitemid 24109343)
26. Cacoub P, Renou C, Rosenthal E, et al. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C. Medicine (Baltimore) 2000; 79:47-56. (Pubitemid 30077736)
27. Ferri C, Zignego AL, Pileri SA. Cryoglobulins. J Clin Pathol 2002; 55:4-13. (Pubitemid 34081673)
28. Lunel F, Musset L. Hepatitis C virus infection and cryoglobulinemia. J Hepatol 1998; 29:848-855. (Pubitemid 28505946)
29. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992; 327:1490-1495.
30. Dammacco F, Sansonno D, Piccoli C, Tucci FA, Racanelli V. The cryoglobulins: an overview. Eur J Clin Invest 2001; 31:628-638. (Pubitemid 32642895)
31. Ferri C. Mixed cryoglobulinemia. Orphanet J Rare Dis 2008; 3:25.
32. Charles ED, Dustin LB. Hepatitis C virus-induced cryoglobulinemia. Kidney Int 2009; 76:818-824.
33. Charles ED, Brunetti C, Marukian S, et al. Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset. Blood 2011; 117:5425-5437.
34. Charles ED, Green RM, Marukian S, et al. Clonal expansion of IgM+CD27+ B cells in HCV-associated mixed cryoglobulinemia. Blood 2008; 111:1344-1356. (Pubitemid 351213421)
35. Ivanovski M, Silvestri F, Pozzato G, et al. Somatic hypermutation, clonal diversity, and preferential expression of the VH 51p1/VL kv325 immunoglobulin gene combination in hepatitis C virus-associated immunocytomas. Blood 1998; 91:2433-2442. (Pubitemid 28155518)
36. Racanelli V, Sansonno D, Piccoli C, D'Amore FP, Tucci FA, Dammacco F. Molecular characterization of B cell clonal expansions in liver of chronically hepatitis C virus-infected patients. J Immunol 2001; 167:21-29. (Pubitemid 32567756)
37. Chan CH, Hadlock KG, Foung SK, Levy S. V(H)1-69 gene is preferentially used by hepatitis C virus-associated B cell lymphomas and by normal B cells responding to the E2 viral antigen. Blood 2001; 97:1023-1026. (Pubitemid 32154288)
38. De Re V, De Vita S, Marzotto A, et al. Pre-malignant and malignant lymphoproliferations in an HCV-infected type II mixed cryoglobulinemic patient are sequential phases of an antigen-driven pathological process. Int J Cancer 2000; 87:211-216. (Pubitemid 30434347)
39. Terrier B, Joly F, Vazquez T, et al. Expansion of functionally anergic CD21-/low marginal zone-like B cell clones in hepatitis C virus infection-related autoimmunity. J Immunol 2011; 187:6550-6563.
40. Marasca R, Vaccari P, Luppi M, et al. Immunoglobulin gene mutations and frequent use of VH1-69 and VH4-34 segments in hepatitis C virus-positive and hepatitis C virus-negative nodal marginal zone B-cell lymphoma. Am J Pathol 2001; 159:253-261. (Pubitemid 33704210)
41. Charles ED, Orloff MI, Dustin LB. A flow cytometry-based strategy to identify and express IgM from VH1-69+ clonal peripheral B cells. J Immunol Methods 2011; 363:210-220.
42. Zehender G, Meroni L, De Maddalena C, Varchetta S, Monti G, Galli M. Detection of hepatitis C virus RNA in CD19 peripheral blood mononuclear cells of chronically infected patients. J Infect Dis 1997; 176:1209-1214. (Pubitemid 27460985)
43. Radkowski M, Gallegos-Orozco JF, Jablonska J, et al. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology 2005; 41:106-114. (Pubitemid 40066388)
44. Mellor J, Haydon G, Blair C, Livingstone W, Simmonds P. Low level or absent in vivo replication of hepatitis C virus and hepatitis G virus/GB virus C in peripheral blood mononuclear cells. J Gen Virol 1998; 79:705-714. (Pubitemid 28161943)
45. Pham TN, King D, Macparland SA, et al. Hepatitis C virus replicates in the same immune cell subsets in chronic hepatitis C and occult infection. Gastroenterology 2008; 134:812-822. (Pubitemid 351312726)
46. Inokuchi M, Ito T, Uchikoshi M, et al. Infection of B cells with hepatitis C virus for the development of lymphoproliferative disorders in patients with chronic hepatitis C. J Med Virol 2009; 81:619-627.
47. Marukian S, Jones CT, Andrus L, et al. Cell culture-produced hepatitis C virus does not infect peripheral blood mononuclear cells. Hepatology 2008; 48:1843-1850.
48. Zeisel MB, Fofana I, Fafi-Kremer S, Baumert TF. Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies. J Hepatol 2011; 54:566-576.
49. Keck ZY, Xia J, Cai Z, et al. Immunogenic and functional organization of hepatitis C virus (HCV) glycoprotein E2 on infectious HCV virions. J Virol 2007; 81:1043-1047. (Pubitemid 46067930)
50. Keck ZY, Li TK, Xia J, et al. Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies. J Virol 2008; 82:6061-6066. (Pubitemid 351822282)
51. Mouquet H, Scheid JF, Zoller MJ, et al. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 2010; 467:591-595.
52. Huang CC, Venturi M, Majeed S, et al. Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. Proc Natl Acad Sci U S A 2004; 101:2706-2711. (Pubitemid 38327675)
53. Zhou T, Xu L, Dey B, et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 2007; 445:732-737. (Pubitemid 46279718)
54. Throsby M, van den Brink E, Jongeneelen M, et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS ONE 2008; 3:e3942.
55. Sui J, Hwang WC, Perez S, et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 2009; 16:265-273.
56. Ekiert DC, Bhabha G, Elsliger MA, et al. Antibody recognition of a highly conserved influenza virus epitope. Science 2009; 324:246-251.